Bispecific-Based Approaches Highlight Key Multiple Myeloma Data Set to Emerge at EHA 2026

June 4, 2026

Chris Ryan

Experts outline the key multiple myeloma presentations they are anticipating at the 2026 EHA Congress.

Roswell Park-Led Study Shows Promise for New Targeted Combination in People With Relapsed AML

June 4, 2026

Roswell Park Comprehensive Cancer Center

New research highlights a promising investigational treatment using ziftomenib in a difficult-to-treat form of acute myeloid leukemia.

HERTHENA-Breast04 Is Set to Delineate the Role of HER3-Targeted Therapy in Advanced HR+ Breast Cancer

June 4, 2026

Ashling Wahner

HER3-DXd is being evaluated in the ongoing phase 3 HERTHENA-Breast04 trial in locally advanced or metastatic HR-positive, HER2-negative breast cancer.

Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL

June 3, 2026

Riley Kandel

Atrial fibrillation was associated with real-world cardiovascular and health care resource utilization burden in CLL/SLL.

Dato-DXd Hits Key Secondary Efficacy End Points in First-Line TNBC

June 3, 2026

Kyle Doherty

Dato-DXd led to benefits in terms of TFST, PFS2, and TSST vs chemotherapy in frontline TNBC.

ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC

June 3, 2026

Ashling Wahner

Post-surgery ctDNA status was prognostic for distant recurrence in early TNBC, and the prognostic value of ctDNA status per WGS outperformed pCR status.

Uncertainties Surrounding HPV Vaccination May Hamper the Full Potential of a Proven Cancer Prevention Strategy

June 3, 2026

Maurie Markman, MD

Maurie Markman, MD, discusses the clinical utility of HPV vaccination as a strategy to prevent malignant disease.

Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg

June 3, 2026

Leah Wells, MD

Leah Wells, MD, breaks down the expansion and continued investigation of ADCs in lung cancer management.

Adjuvant Sintilimab Plus Capecitabine Fails to Improve PFS Over Capecitabine Alone in Suboptimal-Response Locoregionally Advanced NPC

June 3, 2026

OncLive Staff

Sintilimab plus adjuvant capecitabine did not improve 2-year PFS outcomes vs capecitabine alone in NPC with suboptimal response to induction chemotherapy.

ASCO: UT MD Anderson Faculty Honored as 2026 Special Award Recipients

June 3, 2026

MD Anderson Cancer Center

Sharon Giordano will receive the Gianni Bonadonna Breast Cancer Award for significant contributions to breast cancer care and research .

ESAONA Data Support Asandeutertinib as a Frontline Option in EGFR+ NSCLC With Brain Metastases

June 3, 2026

OncLive Staff

First-line asandeutertinib improved intracranial iORR and IPFS vs osimertinib in EGFR-mutated NSCLC with brain metastases.

Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis

June 3, 2026

Riley Kandel

Selinexor plus ruxolitinib produced higher SVR35 rates than ruxolitinib alone in JAK inhibitor-naive myelofibrosis.

HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA

June 2, 2026

OncLive Staff

Zanidatamab plus tislelizumab and chemotherapy improved PFS and OS in HER2-positive mGEA regardless of PD-L1 status by TAP score or CPS.

TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC

June 2, 2026

TALAPRO-3 showed talazoparib plus enzalutamide cut progression or death risk by 52% in HRR-altered mCSPC vs enzalutamide alone.

SERENA-6 Meets PFS2 End Point With Early Switch to Camizestrant in ER+/HER2-Negative, ESR1-Mutated Advanced Breast Cancer

June 2, 2026

Chris Ryan

A switch to camizestrant upon emergence of an ESR1 mutation improved PFS2 in ER-positive, HER2-negative advanced breast cancer.